Artificial intelligence startup Anthropic has established a physical laboratory in the San Francisco Bay Area to conduct biological experiments. In an interview on Tuesday, September 15, 2026, Anthropic's head of life sciences, Eric Kauderer-Abrams, confirmed the existence of the "wet lab," a facility designed for physical scientific research rather than computer-based simulations. While a company spokesperson stated the lab is not specifically for drug discovery, the firm is using it to test how its AI model, Claude, can direct robotic units to perform experiments with limited human intervention.
The move into physical biology follows Anthropic's acquisition of the startup Coefficient Bio, a deal the company confirmed would assist in building drug development tools. Anthropic has also launched a software platform called Claude Science and introduced a Model Hardware Standard in August 2026 to help AI systems operate laboratory equipment. The company's leadership stated that the initiative is intended to address rare diseases that the traditional pharmaceutical industry may neglect for financial reasons.
Kauderer-Abrams reported that life sciences is currently one of Anthropic's largest investment areas by both resources and headcount. The company has posted job listings for experts in biochemical work, including protein and nucleic acid characterization, and a leadership role to manage laboratory procurement. Despite these internal developments, Anthropic continues to provide AI services to major pharmaceutical firms including Genentech, Bristol Myers Squibb, and Novo Nordisk.
For the average person, this shift could eventually change how quickly new medicines reach the market, though the timeline remains long. Currently, the industry standard for bringing a new drug through human trials to market takes several years. Anthropic’s competitors, such as Alphabet’s Isomorphic Labs, have already faced delays, pushing their clinical goals to the end of 2026. A person would not see an immediate change in their pharmacy bills or health care access, as Anthropic stated it is currently focused on preclinical work and is not yet running its own clinical trials.
The precedent set by a major AI developer building its own physical laboratory marks a transition from software-based research to direct physical automation. This move raises questions regarding data privacy and competition, as Anthropic serves traditional pharmaceutical clients while developing its own internal programs. While the company stated it walls off client data, two people familiar with the matter indicated that customers may have concerns about competing programs. The next steps for the company include scaling its lab operations and continuing to develop AI tools that can automate laboratory execution with human oversight.